Intensity Therapeutics, Inc.

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:01 18/07/2024 am IST			5-day change	1st Jan Change
4.84 ^USD	-1.63%		-1.22%	-43.52%

09/07	Intensity Therapeutics, Inc. Announces First Patient Dosed in Its Global Randomized, Phase 3 Study (Invincible-3) in Metastatic Soft Tissue Sarcoma	CI
01/07	Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell Microcap Value Index	CI

Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell Microcap Value Index

July 01, 2024

Latest news about Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. Announces First Patient Dosed in Its Global Randomized, Phase 3 Study (Invincible-3) in Metastatic Soft Tissue Sarcoma	09/07	CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell Microcap Value Index	01/07	CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell 3000E Value Index	01/07	CI
Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors	15/05	CI
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	11/05	CI
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	10/05	MT
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	20/04	CI
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	03/01	DJ
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12	CI
Certain Warrants of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12	CI
Certain Stock Options of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12	CI
Intensity Therapeutics Names Joseph Talamo as Finance Chief	12/12	MT
Intensity Therapeutics, Inc. Announces Appointment of Joseph Talamo as Chief Financial Officer	12/12	CI
Sector Update: Health Care Stocks Rise Late Afternoon	09/12	MT
Sector Update: Health Care	09/12	MT
Top Midday Gainers	09/12	MT
Intensity Therapeutics Says Breast Cancer Treatment Showed Tumor Necrosis in Phase 2 Trial; Shares Jump	08/12	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Intensity Therapeutics, Inc. Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023	02/11	CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) added to S&P TMI Index	18/23/18	CI
Intensity Therapeutics Gets Orphan Drug Label for Three Ingredients in INT230-6	07/23/07	MT
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI

Chart Intensity Therapeutics, Inc.

Duration

Period

More charts

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patientâs cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.84 USD

Average target price

14 USD

Spread / Average Target

+189.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTENSITY THERAPEUTICS, INC.	-43.52%	6.64Cr
MODERNA, INC.	+24.74%	4.75TCr
IQVIA HOLDINGS INC.	-0.47%	4.2TCr
LONZA GROUP AG	+48.94%	4.16TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.04TCr
ICON PUBLIC LIMITED COMPANY	+17.96%	2.76TCr
CELLTRION, INC.	-4.47%	2.87TCr
UNITED THERAPEUTICS CORPORATION	+50.73%	1.47TCr
MEDPACE HOLDINGS, INC.	+42.56%	1.35TCr
BIO-TECHNE CORPORATION	+1.46%	1.23TCr

Other Biotechnology & Medical Research